Related Experiment Videos
Homocysteine as a cardiovascular risk factor
1Nephrology and Dialysis Unit, Legnago Hospital, Legnago/VR, Italy.
Blood Purification
|June 22, 2000
Summary
Hyperhomocysteinemia (HH) is common in hemodialysis patients and increases vascular disease risk. While vitamin supplementation and dialysis membranes can lower homocysteine (Hcy) levels, new strategies are needed for normalization.
Area of Science:
- Nephrology
- Vascular Biology
- Nutritional Biochemistry
Background:
- Hyperhomocysteinemia (HH) is a frequent complication in hemodialysis (HD) patients, posing a significant risk for vascular diseases.
- Elevated homocysteine (Hcy) levels induce oxidative stress, leading to endothelial dysfunction, impaired vasodilation, and reduced antithrombotic properties.
Purpose of the Study:
- To evaluate strategies for reducing plasma homocysteine (P-Hcy) concentrations in hemodialysis patients.
- To assess the efficacy of vitamin supplementation and different dialysis membrane types in managing HH.
Main Methods:
- A 1-year clinical experience comparing paired filtration dialysis, bicarbonate dialysis, and acetate-free biofiltration.
- Administration of vitamin B6, B12, and folic acid supplementation.
- Analysis of plasma homocysteine (P-Hcy) levels before and after interventions.
Main Results:
- Vitamin supplementation (B6, B12, folic acid) reduced basal Hcy levels by approximately 40% within six months.
- Hemodialysis membranes influenced P-Hcy reduction, with noncellulosic membranes showing higher efficacy (41%) than cellulosic membranes (29%).
- Paired filtration dialysis demonstrated superior results compared to other dialysis techniques over the 1-year study period.
Conclusions:
- Neither vitamin supplementation nor current dialysis techniques alone can normalize P-Hcy levels in HD patients.
- Novel therapeutic approaches, including absorption techniques, liposomal delivery, and new supplementation strategies, are necessary to effectively manage HH in this population.